Protagenic Therapeutics, Inc.\new (PTIX) Operating income 2018–2026
Protagenic Therapeutics, Inc.\new (PTIX) annual operating income history from SEC filings — each fiscal year as reported.
-$4.5MFY2026 · since FY2018: -$2.4M → -$4.5M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2026 | -$4.5M | -73.6% |
| FY2025 | -$2.6M | +42.7% |
| FY2024 | -$4.5M | -27.2% |
| FY2023 | -$3.6M | +14.1% |
| FY2022 | -$4.1M | -62.3% |
| FY2021 | -$2.6M | -22.3% |
| FY2020 | -$2.1M | +9.9% |
| FY2019 | -$2.3M | +2.2% |
| FY2018 | -$2.4M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More PTIX financial trends
PTIX RevenuePTIX Net incomePTIX Net marginPTIX Gross profitPTIX Gross marginPTIX Operating marginPTIX Operating cash flowPTIX Free cash flowPTIX Capital expendituresPTIX Return on equityPTIX Stock buybacksPTIX Dividends paidPTIX Total assetsPTIX Total liabilitiesPTIX Shareholders’ equityPTIX overview →